Burning Rock Biotech Limited (BNR) delivered a return of 147.67% over the past year. Since BNR does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Burning Rock Biotech Limited one year ago would be worth $24,767 today, representing a gain of $14,767.

Burning Rock Biotech Limited (BNR) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For BNR, the total return equals the price-only return.

Yes, Burning Rock Biotech Limited (BNR) outperformed the S&P 500 by 126.83 percentage points over the past year. BNR delivered a total return of 147.67%, compared to the S&P 500's 20.84%. This 126.83pp alpha means investors in BNR earned more than a passive S&P 500 index fund.

Burning Rock Biotech Limited (BNR) experienced a maximum drawdown of -82.85% over the past year, declining from its peak on 2026-01-22 to its trough on 2026-06-17. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Burning Rock Biotech Limited (BNR)'s long-term returns with dividends reinvested. Over 10 years, the total return is -96.5% (-28.6% CAGR) — $10,000 would have grown to $346. Over 20 years: -96.5% total return (-15.5% CAGR) — $10,000 → $346. Over 30 years: -96.5% total return (-10.6% CAGR) — $10,000 → $346. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Burning Rock Biotech Limited's best calendar year was 2025 with a total return of 172.7%. Its worst year was 2022 with a total return of -78.0%. This range shows the volatility investors should expect — the difference between the best and worst year is 250.7 percentage points.